Drug intelligence / Profile preview

ethambutol + rifabutin

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Ethambutol + rifabutin is a combination of two antimycobacterial drugs used primarily for the treatment of Mycobacterium avium complex (MAC) infections, particularly in patients with HIV/AIDS. This combination produces an additive inhibitory effect against most MAC strains, with synergistic effects observed in some cases. The combination reduces the minimal inhibitory concentrations for each drug and demonstrates synergistic bactericidal activity. Ethambutol works by inhibiting arabinosyltransferases in mycobacterial cells, preventing formation of cell wall components. Rifabutin is an ansamycin antibiotic that inhibits DNA-dependent RNA polymerase in susceptible bacteria.

Targets

rpoB (DNA-directed RNA polymerase subunit beta)AftA (Arabinosyltransferase AftA)

Beyond the preview

Go deeper on ethambutol + rifabutin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ethambutol + rifabutin.

Explore the full profile